XThis page contains elements that are not optimised for mobile viewing. Click the link below to view the page in desktop mode.
Desktop mode

Danish Pharmacovigilance Update, March 2017

18 April 2017

In this issue

  • The European Pharmacovigilance Risk Assessment Committee, PRAC, recommends regulatory measures – including suspension of the marketing authorisation for some gadolinium-containing contrast agents
  • The DKMA seeks more knowledge about the use of quetiapine in children and adolescents
  • Childhood vaccinations and reported suspected adverse reactions in Q4 of 2016
  • EU's list of recommendations on safety signals
  • Most recent Direct Healthcare Professional Communications (DHPCs)

Link

Danish Pharmocovigilance Update, March 2017

Did you get answers to your questions?

Please tell us how we can improve our website?